Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LifewardLFWD +0.99%56 EV-to-EBIT is -0.90 as of Jul. 18, 2026. GuruFocus rates LFWD with a GF Score™ of 56/100 and a GF Value™ of $13.79 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 466 Medical Devices & Instruments companies, Lifeward ranks worse than 214592.06% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Lifeward's Enterprise Value for the quarter that ended in Mar. 2026 was $15.82 Mil.
Lifeward's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lifeward EV-to-EBIT Related Terms
Lifeward EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Lifeward's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Lifeward's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lifeward EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lifeward's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Lifeward's EV-to-EBIT falls into.
Lifeward's current Enterprise Value is $19.65 Mil.
Lifeward's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lifeward (LFWD) has a EV-to-EBIT of -0.90 as of Jul. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lifeward and its competitors. According to the industry distribution chart, Lifeward ranks #999999 out of 466 companies in the Medical Devices & Instruments industry.
Is Lifeward's EV-to-EBIT too high?
Lifeward's current EV-to-EBIT is -0.90. Based on the distribution chart, Lifeward ranks #999999 out of 466 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Lifeward has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lifeward's EV-to-EBIT compare to ICCM and IRIX?
According to the Medical Devices & Instruments industry distribution chart, Lifeward ranks #999999 out of 466 companies for EV-to-EBIT. This places Lifeward in the lower half of its industry. The industry median EV-to-EBIT is 18.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.46, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lifeward and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lifeward's current EV-to-EBIT is -0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifeward stock overvalued right now?
Based on GuruFocus' analysis, Lifeward (LFWD) is currently considered Possible Value Trap. The stock's GF Value™ is $13.79, compared to a current price of $7.91 — trading 42.6% below its estimated fair value. The current EV-to-EBIT is -0.90. Lifeward's overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Lifeward (LFWD), the current EV-to-EBIT is -0.90 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lifeward (LFWD) Overvalued in 2026?
Based on GuruFocus' analysis, Lifeward stock appears to be undervalued.
The current stock price of $7.91 is trading 42.6% below its estimated GF Value™ of $13.79.
GuruFocus considers Lifeward to be Possible Value Trap.
Key valuation signals for LFWD:
EV-to-EBIT: -0.90
GF Value™: $13.79 vs. price of $7.91 (42.6% below fair value)
No single metric tells the full story. See the LFWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions spanning the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings include the ReWalk Personal Exoskeleton, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. The company operates in the United States, which generates the majority of its revenue, as well as in Europe, Germany, Asia Pacific, and the rest of the world.
56GF Score
Get the complete analysis for LFWD
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFWD has been successfully added to your 
